<?xml version="1.0" encoding="UTF-8"?>
<supplementary-material content-type="local-data" id="MOESM1">
 <media xlink:href="12936_2020_3552_MOESM1_ESM.docx" xmlns:xlink="http://www.w3.org/1999/xlink">
  <caption>
   <p>
    <bold>Additional file 1: Fig. S1.</bold> Isolation protocol of knipholone (
    <bold>2</bold>). 
    <bold>Fig. S2.</bold> Isolation protocol of dianellin (
    <bold>1</bold>). 
    <bold>Fig. S3.</bold> I: 
    <sup>1</sup>H, 
    <sup>13</sup>C, DEPT and HRMS of YKFM-2 (Dianellin). 
    <bold>Fig. S4.</bold> II: 
    <sup>1</sup>H, 
    <sup>13</sup>C, DEPT and HRMS of KFP-1 (Knipholone). 
    <bold>Table S1.</bold> Antimalarial activity of the phenolic fractions of 
    <italic>Kniphofia folosia</italic> in mice infected with 
    <italic>Plasmodium berghei</italic>. 
    <bold>Table S2.</bold> Prediction of partition coefficient Log P, aqueous solubility Log S and partition coefficient for partially dissociated compounds Log D of the compounds. 
    <bold>Table S3.</bold> Docking result of compounds on the crystal structure of plasmepsin II (4cku) and plasmodium falciparum l-lactate dehydrogenase (pfLDH) (PDB 1ldg). 
    <bold>Table S4.</bold> Acute oral toxicity results of dianellin. 
    <bold>Fig. S4.</bold> Microscope slide photos of the negative control groups (A and B), dianellin and knipholone treated groups (C-E) and positive control group (F).
   </p>
  </caption>
 </media>
</supplementary-material>
